Help Wanted: FDA Recruiting New CBER Director Ahead Of Gene, Cell Therapy Wave
This article was originally published in RPM Report
Executive Summary
CBER Director Midthun is stepping down at the end of the year, just as the center is moving into an era of more hands-on work in reviewing new therapeutics.
You may also be interested in...
Keeping Track: US FDA's Late Summer Approval Extravaganza Stars Three Novel Agents, Features Return Of Mylotarg
Kymriah, Vabomere, and benzidazole approvals joined by new indications for Austedo, Faslodex.
House ALS Bill Would Require US FDA ‘Action Plan’ – But Not Conditional Approval
US House of Representatives if moving forward with a bill to respond to advocacy from ALS patients for more attention from FDA. The bill focuses on planning and scientific support, not new pathways.
Providers Still See Drawbacks To Opioid Education Mandates
Participants in a US FDA meeting on opioid REMS did not treat a move to mandatory education as a foregone conclusion. Instead, they delved frequently into alternate approaches to enhance the education itself.